The choices of psychedelic stocks available for investors and where to put your money to work in the sector are slim. Some are doing amazing research and others are planning to according to their press releases.
That is certainly changing, and for the better.
A publicly traded company, who has actually been one of the first movers in the psychedelics industry, has quietly been conducting the science (not just saying they plan to).
Wuhan ventured to South Africa - missing the eye of investors.
In Wuhan General Group’s (WGG)
latest corporate presentation they are lifting the veil for their concluded in vivo and in vitro pre-clinical research with psilocybin and planned phase 1 human trials.
The shares are trading at a massive discount relative to their competition.
It is only a matter of time, before the stock price and valuation catches up.